Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr:10:e2300379.
doi: 10.1200/GO.23.00379.

Lung Cancer Clinical Trials in Latin America in the Era of Cooperative Groups: A 20-Year Analysis

Thomas Knapp  1 , Joseph Nygaard  1 , Joshua Cassinat  1 , Fernando Galvez  2 , Priya K Gopalan  3
Affiliations

Lung Cancer Clinical Trials in Latin America in the Era of Cooperative Groups: A 20-Year Analysis

Thomas Knapp et al. JCO Glob Oncol. 2024 Apr.

Abstract

Purpose: The aim of this study is to characterize lung cancer treatment clinical trials in Latin America before (January 2001-December 2011) and after (January 2012-December 2021) the organization of major Latin American oncology cooperative groups.

Materials and methods: Interventional clinical trials were identified in ClinicalTrials.gov using the search terms "lung cancer," country filters for 20 Latin American countries, and study start dates January 1, 2001-December 31, 2011, and January 1, 2012-December 31, 2021. Clinical trials were categorized as either originating in Latin America (LA) or outside Latin America (non-LA) with participation of Latin American countries. Descriptive statistics, two-sided Z-scores, and chi-square analyses with 95% CIs were calculated.

Results: Overall, 273 clinical trials involving Latin American countries between 2001 and 2021 were identified. Comparing 2001-2011 with 2012-2021, there was an increase in total clinical trials (100 v 173; P < .001). Only 9% (26 of 273) of all trials were LA trials. There was a marked decrease in the proportion of LA trials (14% v 7%, P = .058) and estimated enrollment to LA trials (3,245 v 1,190 patients; P < .001). Recruiting of patients with EGFR (29% v 7%; P < .01) and KRAS (18% v 2%; P < .01) driver mutations also decreased. Trial participation was highest in Brazil, Mexico, Argentina, Chile, and Peru and increased over time: Brazil (61 v 108; 77% increase), Mexico (40 v 88; 120% increase), Argentina (50 v 78; 56% increase), Chile (25 v 57; 128% increase), and Peru (14 v 37; 164% increase).

Conclusion: There was a significant increase in clinical trial participation by Latin American countries, from 2001-2011 to 2012-2021. However, there were few clinical trials which originated in Latin America or focused on patients with driver mutations.

PubMed Disclaimer

Conflict of interest statement

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/go/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

No potential conflicts of interest were reported.

Figures

FIG 1
FIG 1
Total number of clinical trials, number of trials, and percent increase in clinical trial participation by era for highest contributing Latin American countries.
See this image and copyright information in PMC

References

    1. Arrieta O, Zatarain-Barrón ZL, Cardona AF, et al. : Uniting Latin America through research: How regional research can strengthen local policies, networking, and outcomes for patients with lung cancer. Am Soc Clin Oncol Educ Book 42:1-7, 2022 - PubMed
    1. Raez LE, Cardona AF, Santos ES, et al. : The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments. Lung Cancer 119:7-13, 2018 - PubMed
    1. Raez LE, Nogueira A, Santos ES, et al. : Challenges in lung cancer screening in Latin America. JCO Glob Oncol 10.1200/JGO.17.00040 - DOI - PMC - PubMed
    1. Piñeros M, Laversanne M, Barrios E, et al. : An updated profile of the cancer burden, patterns and trends in Latin America and the Caribbean. Lancet Reg Health Am 13:100294, 2022 - PMC - PubMed
    1. Martin C, Cuello M, Barajas O, et al. : Real-world evaluation of molecular testing and treatment patterns for EGFR mutations in non-small cell lung cancer in Latin America. Mol Clin Oncol 16:6, 2022 - PMC - PubMed